FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Venlafaxine Hydrochloride Extended-Release Tablets. The approved indications are for the treatment of depression, including depression accompanied by anxiety, and generalized anxiety disorder. The drug is a chemically synthesized pharmaceutical independently developed by the group. As of April 2026, the cumulative R&D investment for this drug by the group amounted to approximately RMB 7.68 million (unaudited). The market approval of this product is expected to further diversify the group's portfolio of related pharmaceutical formulations.